Study of a novel Multicomponent Meningococcal Group B Vaccine When Given Alone or With Other Licensed Vaccines in Adults, Adolescents, Toddlers and Infants

Trial Identifier: VAN00002
Sponsor: Sanofi Pasteur, a Sanofi Company
Start Date: March 2021
Primary Completion Date: July 2022
Study Completion Date: July 2022
Condition: Healthy Volunteers; Meningococcal Immunisation

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
Puerto Rico San Juan, Puerto Rico, 00918
PUERTO RICO Ponce, PUERTO RICO, 00716
United States, Alabama Guntersville, Alabama, United States, 35976-2206
United States, California SAN DIEGO, California, United States, 92123-1881
United States, South Carolina Greenville, South Carolina, United States, 29607
UNITED STATES, Alabama Guntersville, Alabama, UNITED STATES, 35976-2206
UNITED STATES, Florida Tampa, Florida, UNITED STATES, 33613
UNITED STATES, Indiana Indianapolis, Indiana, UNITED STATES, 46260
UNITED STATES, Kansas El Dorado, Kansas, UNITED STATES, 67042
UNITED STATES, Kansas Wichita, Kansas, UNITED STATES, 67205
UNITED STATES, New York Bronx, New York, UNITED STATES, 10456